Humanin: The Neuroprotective Mitochondrial Peptide
Last updated: March 2026
Humanin is the first discovered mitochondrial-derived peptide — a 24-amino acid sequence encoded within the mitochondrial genome. Identified in 2001 as a neuroprotective factor, it blocks apoptosis, reduces oxidative stress, improves insulin sensitivity, and declines significantly with age.
in Sequence
Discovered
Young → Old
📋 On this page
The 2001 Discovery Story
Found by accident in Alzheimer's brain tissue — Humanin changed how we think about mitochondria.
In 2001, Dr. Yasuomi Hashimoto and colleagues at Tokyo's Institute of Medical Science were screening a cDNA library from the occipital lobe of an Alzheimer's patient. A short, previously unknown sequence — encoded not by nuclear DNA but by the mitochondrial 16S rRNA region — completely protected neurons from amyloid-beta-induced cell death. They named it Humanin.
Humanin is encoded within the 16S rRNA gene of the mitochondrial genome — the same genome that manages cellular energy production. It is the first known peptide derived from mitochondrial DNA.
The Hashimoto lab found that even nanomolar concentrations of Humanin prevented neuron death triggered by familial Alzheimer's disease genes (APP, PSEN1, PSEN2) and amyloid-beta peptides in cell cultures.
Humanin is not just intracellular. It is secreted into circulation — acting as a "mitokine" — communicating the mitochondria's status to distant tissues including the brain, liver, pancreas, and gonads.
Later studies confirmed Humanin is detectable in human blood serum and cerebrospinal fluid. This opened the door to studying it as both a biomarker and a potential therapeutic target.
How Humanin Works
Humanin operates through multiple pathways — blocking cell death, neutralizing oxidative damage, and modulating growth factor signaling.
Humanin binds and sequesters the pro-apoptotic protein BAX. By preventing BAX from migrating to the mitochondrial outer membrane, Humanin blocks the intrinsic apoptosis cascade before it starts.
Humanin activates the JAK2/STAT3 survival signaling pathway — a powerful anti-apoptotic and cytoprotective cascade active in neurons, cardiomyocytes, and immune cells.
Humanin interacts directly with IGFBP-3 and competes with IGF-1 for receptor binding. This modulates insulin-like growth factor signaling, influencing both neuroprotection and metabolic function.
Humanin reduces reactive oxygen species (ROS) production and lipid peroxidation. In neural and cardiac cells under oxidative stress, it preserves mitochondrial membrane potential and cell viability.
Humanin improves insulin sensitivity partly via AMPK activation — the same pathway as metformin and exercise. In metabolic models, it improves glucose uptake and reduces hepatic fat accumulation.
Reduces infarct size in cardiac ischemia-reperfusion models. Protects vascular endothelial cells from apoptosis and atherosclerosis-promoting lipid peroxidation.
Age-Related Decline
Humanin levels drop progressively with age — and lower levels correlate with worse health outcomes.
Values are approximate and based on comparative data across multiple studies. Individual variation is significant.
Cohort data from the USC Davis School of Gerontology found that older adults with higher Humanin levels showed better cognitive performance. Alzheimer's patients have significantly lower serum Humanin vs. age-matched controls.
Age-associated Humanin decline may contribute to worsening insulin sensitivity, increased visceral fat, and reduced mitochondrial efficiency — all hallmarks of metabolic syndrome and type 2 diabetes risk.
What the Research Shows
Preclinical evidence is strong across multiple disease models. Human data is emerging but limited.
Alzheimer's Disease Research
Metabolic Syndrome Research
Additional Protective Effects
The Mitochondrial Peptide Family
Humanin belongs to a growing family of mitochondria-derived signaling peptides — each with distinct but complementary mechanisms.
24-AA. First MDP discovered. Anti-apoptotic, neuroprotective. Declines ~40% with age. JAK2/STAT3 and BAX inhibition.
16-AA mitochondrial peptide. AMPK activator. Metabolic benefits and physical performance. "Exercise in a peptide."
Targets cardiolipin in inner mitochondrial membrane. Phase 3 trials for heart failure. Restores cristae structure.
4-AA tetrapeptide bioregulator. Activates telomerase, extends telomeres. Longevity, circadian, and antioxidant effects.
Browse all researched peptides, mechanisms, and clinical data in our interactive compound database.
Full library of HighPeptides research infographics — longevity, healing, cognitive, metabolic, and more.
Safety Considerations
Humanin has a favorable preclinical safety profile, but human data is sparse. Risk assessment is primarily extrapolated from animal models.
Ideal Candidate Profile
Humanin research is most relevant for specific clinical contexts — age-related neurodegeneration and metabolic dysfunction are the primary areas of interest.
- Adults 45+ interested in longevity and mitochondrial health research
- Individuals with confirmed Humanin deficiency (via clinical testing)
- Research interest in Alzheimer's disease biomarker tracking
- Metabolic syndrome with concurrent interest in mitochondrial function
- Those following mitochondrial peptide research (MOTS-c, SS-31)
- Participants in supervised clinical investigation protocols
- Under 30 years old without specific medical context
- Anyone with active or history of hormone-sensitive cancers
- Currently pregnant or breastfeeding
- Individuals on IGF-1 or insulin therapy without physician oversight
- Anyone expecting clinical benefits — no human efficacy trials completed
- Those seeking a standalone Alzheimer's treatment
Important framing: Humanin is currently a research tool, not a therapeutic. The appropriate use is in clinical research contexts with proper oversight. Consumer use is premature given the current evidence base.
Key Study Citations
Key Takeaways
- First mitochondrial-derived peptide, discovered 2001
- 24-amino acid sequence encoded in mtDNA (16S rRNA region)
- Potent anti-apoptotic via BAX inhibition + JAK2/STAT3 activation
- Reduces amyloid-beta toxicity in cell and animal Alzheimer's models
- Levels decline ~40% from young adulthood to age 70+
- Improves insulin sensitivity and metabolic markers in animal studies
- Protects cardiac tissue in ischemia-reperfusion models
- Circulates as a "mitokine" — systemic inter-organ signaling molecule
- No completed human Phase 2/3 clinical trials
- Optimal dose, route, and frequency in humans not established
- Long-term safety profile in humans unknown
- Net effect of IGFBP-3 competition on growth factor signaling
- Whether supplemental Humanin actually reduces Alzheimer's risk in humans
- Bioavailability and half-life in human circulation
- Cancer risk implications of chronic IGF-1 axis modulation
🔬 Verified Research Source
Third-party tested compounds from Swiss Chems — one of the most trusted research suppliers.
Affiliate link — supports HighPeptides at no extra cost. All Swiss Chems products include third-party lab testing certificates.
🛒 Recommended Products
Support supplements for mitochondrial health and peptide research.
Affiliate links help support HighPeptides at no extra cost to you.
🔗 Related Resources
Want the Complete Protocol Guide?
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
Get the Guide →
This page is for educational and informational purposes only. Humanin is a research peptide not approved by the FDA or any regulatory body. All data cited comes from preclinical studies (cell culture and animal models) and early-phase human research. No large human clinical trials have been completed. The safety and efficacy of Humanin in humans has not been established. Always consult a qualified, licensed healthcare provider before starting any new compound. Nothing on this page constitutes medical advice.